Mantle cell lymphoma
Found 6 free book(s)
Japanese classification of gastric carcinoma: 3rd English ...
www.jgca.jpLymphoma B-cell lymphoma MALT (mucosa-associated lymphoid tissue) lymphoma 9699/3 Follicular lymphoma 9690/3 Mantle cell lymphoma 9673/3 Diffuse large B-cell lymphoma 9680/3 Other B-cell lymphomas T-cell lymphoma Other lymphomas Metastatic tumor Tumor-like lesion Hyperplastic polyp Fundic gland polyp Heterotopic submucosal gland Heterotopic ...
BC Cancer Protocol Summary for Treatment of Lymphoma …
www.bccancer.bc.camantle cell lymphoma ... Patients with paranasal sinus involvement with large cell lymphoma who have a complete response at the completion of their chemotherapy should receive intrathecal methotrexate 12 mg alternating with intrathecal cytarabine 50 mg twice weekly x 6 doses (3 doses of each over 3 weeks) starting in week 18. ...
MaxiCHOP / High Dose Ara-C + Rituximab
nssg.oxford-haematology.org.ukAuthorised by Lymphoma lead Dr. Graham Collins June 2021 Published: May 2021 Review: May 2023 Version 1.8 1 of 10 MaxiCHOP / High Dose Ara-C + Rituximab INDICATION Newly diagnosed, previously untreated mantle cell lymphoma (stage II to IV), in patients fit for intensive treatment (including stem cell transplantation). TREATMENT INTENT
REVLIMID U.S. Prescribing Information - BMS
packageinserts.bms.com• Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). • Previously treated follicular lymphoma (FL), in combination with a rituximab product (1.4). • rash (6.1).Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product (1.5).
DRUG NAME: Rituximab
www.bccancer.bc.camay occur in patients with an initial high tumour burden (e.g., CLL, mantle cell lymphoma). Treat with extreme caution, at a reduced infusion rate, and closely monitor for signs of tumour lysis syndrome during the first infusion .
NSSG Chemotherapy Protocol
nssg.oxford-haematology.org.ukNewly diagnosed mantle cell lymphoma, with or without rituximab, instead of intravenous chemotherapy, in order to reduce toxicity of treatment and number of admissions required. COVID Blueteq approval is required TREATMENT INTENT Induction and maintenance of remission.